MedTrace Logo

FoxO3a and PU.1 in Acute Lymphoblastic Leukemia

NCT04092348 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 53

Last updated 2023-02-08

No results posted yet for this study

Summary

Acute Lymphoblastic Leukemia (ALL) is one of the four major types of leukemia which is common in both children and adolescents; however, it is the most common pediatric malignancy diagnosed in children younger than 20 years .The disease pathogenesis results from blockade at any stages of normal lymphoid differentiation with uncontrolled proliferation of lymphoid cells. According to the World Health Organization (WHO) definition, ALL is categorized in B-Lymphoblastic Leukemia (B-ALL) And T-Lymphoblastic Leukemia (T-ALL), originated from B- and T-Lineage lymphoid precursor cells, respectively.

Conditions

Interventions

OTHER

complete blood count

1. total RNA is isolated from fresh blood samples 2. RNA is converted into complementary DNA c.DNA 3. cDNA is then analysed by quantitatine Real Time PCR(qRT-PCR) to evaluate the relative expression levels of FoxO3a, PU.1 genes and TATA-binding protein (TBP) ,as an endogenous control gene.

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Eligibility

Min Age
2 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-01
Primary Completion
2024-03-30
Completion
2024-12-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04092348 on ClinicalTrials.gov